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A process is described to assess the commutability of a
reference material (RM) intended for use as a calibrator
based on its ability to fulfill its intended use in a calibra-
tion traceability scheme to produce equivalent clinical
sample (CS) results among different measurement proce-
dures (MPs) for the same measurand. Three sources of
systematic error are elucidated in the context of creating
the calibration model for translating MP signals to mea-
surand amounts: calibration fit, calibrator level trueness,
and commutability. An example set of 40 CS results from
7MPs is used to illustrate estimation of bias and variabil-
ity for each MP. The candidate RM is then used to reca-
librate each MP, and its effectiveness in reducing the
systematic error among the MPs within an acceptable
level of equivalence based on medical requirements con-
firms its commutability for those MPs. The RM is de-
clared noncommutable for MPs for which, after recali-
bration, the CS results do not agree with those from other
MPs. When a lack of agreement is found, other potential
causes, including lack of calibration fit, should be inves-
tigated before concluding the RM is noncommutable.
The RM is considered fit for purpose for those MPs
where commutability is demonstrated.
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Background
The goal of providing a higher order reference material
(RM)15 is to ensure that any clinical sample (CS) will
have equivalent results across measurement procedures
(MPs), within an uncertainty consistent with medical
decision requirements.When the results for multiple CSs
obtained with multiple MPs are compared, the differ-
ences are caused by the following types of errors:
• Random errors within MPs
• Sample-specific differences between MPs
• A bias between MPs (a function of the concentration)
The causes of the bias error can be an inappropriate
model for the calibration curve, incorrect values assigned
to the calibrators, and a difference in behavior between
calibrators and CSs (not the same relationship between
concentration and response). The bias error can be re-
duced by recalibration with a suitable RM or set of RMs.
Consequently, the commutability of an RM can be as-
sessed by how well bias among measurements of CSs is
reduced when that RM is used in the calibration trace-
ability schemes of different MPs. The approach to com-
mutability assessment described here is applicable for
RMs intended for use as calibrators in a calibration hier-
archy described in ISO 17511 (1 ).
The success of such an assessment process depends
on how well each MP is designed and implemented.
Therefore, the reasons for any bias remaining after reca-
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libration with an RM should be investigated before the
RM is characterized as noncommutable with anMP. For
example, if the remaining bias is caused by nonselectivity
of anMP, or by an inadequate design or implementation
of the MP, then the measurement issues of that MP need
to be addressed rather than concluding the RM is not
suitable for use. To assess the commutability of an RM,
estimates of systematic errors (bias) must be determined.
This determination must be done within data sets where
random variation is present and when sample interfer-
ences for specific samples on specific MPs may be seen.
Therefore, throughout the following assessment, esti-
mates of systematic error are determined using order sta-
tistics that are little affected by outlying results (e.g.,
median).
As explained in part 1 of this series (2 ), anMP refers
to a written specification for how a measurement is per-
formed. A measuring system is a physical in vitro diag-
nostic (IVD) medical device manufactured according to
the MP specifications and used to make measurements
on CSs. Results for an RM and for CSs measured using
different measuring systems are used to assess commut-
ability of an RM. For simplicity, in this series of reports
we use the term MP when referring to either an MP or
results from a specific measuring system that is an IVD
medical device representative of the MP.
Calibration Process and Sources of Error
Before clinically relevant results can be reported, the MP
that produces those results must be calibrated with a suit-
able number of calibrator levels. Although CS-specific
issues such as interferences are not relevant for the cali-
bration process, random variation does play a role. The
manufacturer must create a process that ensures true re-
sults by choosing a reproducible calibration scheme
traceable to the highest order reference available. In the
simplest case, a calibration relationship is established by
measuring the signal created by the MP when calibrator
samples of stated concentration (i.e., amount of sub-
stance present or quantity value) are tested and fit to a
linear regression:
y      xs   (1)
where y is the signal,  is the random variation in the
signal, xs is the stated concentration of the calibrator lev-
els used,  is the linear regression intercept, and  is the
linear regression slope. A more complex, 4-parameter lo-
gistic curve model is presented in the Data Supplement
that accompanies the online version of this article at
hiip://www.clinchem.org/content/vol64/issue3. Re-
gardless of the type of calibration fit, the signal random
variation  can be characterized with a precision profile
across the concentration interval, typically assuming a
normal distribution on the signal axis.
During the calibration process, sources of systematic
error include the following:
• The lack of fit of the mathematical model characteriz-
ing the relationship between signal and concentration.
This lack of fit can be described by a function f, which
is the ratio of the observed signal to the model fit.
When the MP calibration model fits through all the
signal results from each of the calibrator samples, then
f  1 across the concentration interval.
• The degree to which the stated concentrations of the
calibrator samples are not true values, as defined by
traceability to a specified RM. The ratio of stated to
true concentration across the concentration interval
can be described by a function g. When all MP calibra-
tor sample values are assigned via a traceability scheme
created with the specified RM, then g  1 across the
concentration interval. Such a value assignment is
most accurate if f  1. This report describes an ap-
proach to assessing the commutability of this RM
when it is used in the calibration hierarchy of the cali-
brators used in a clinical laboratory MP.
• The extent to which the stated concentrations of the
calibrator samples, traceable to the RM being assessed,
are equal to measurement results from authentic CS
having the same concentration. The extent of this
equivalence, or commutability, can be described by a
function h, which is the ratio of observed CS results vs
their consensus target results. If, after setting g  1
using the RM, CS samples give their consensus target
results on a specified MP, then h  1 across the con-
centration interval for that MP.
When the functions g and h are not equal to 1, then they
are systematic error terms that modify the true concen-
tration x such that its estimated value is
xˆ  x  g  h (2)
The function f is an error term that characterizes the
model fit to the signal response over the entire concen-
tration interval. Although this function may change
somewhat at the creation of each calibration curve, the
goal of using this function is to describe a systematic
calibration fit error that is integral toMP design. Because
none of the error terms can be assumed to be constant
across the measuring interval, the amount of error intro-
duced by each error function depends on the position (i)
on the calibration curve of signal vs concentration. This
error at each concentration is described in the expanded
equation
yi  fi      xi  gi  hi  i (3)
Curve fitting algorithms can use a closed-form solution
such as a least-squares regression, a numerical solution
such as a nonlinear iterative fit to a 4-parameter logistic
curve, or a piecewise solution that can incorporate both
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approaches like a cubic spline fit. All such algorithms
attempt to make fi as close to unity as possible, typically
using the signal precision profile i to weight the fitting
process. A common approach is to weight the fit to a
calibration point (xi, yi) by the inverse of i
2 at the con-
centration of that point. Once the calibration curve is
created, then it is used to determine the concentration
value of CSs. Solving for xi, the equation becomes
xi   yi  fi  /  gi  hi  ei (4)
The random signal error term i contributed by the signal
during the calibration process is not retained. The term ei
is the random error on the concentration scale that typi-
cally is assumed to be normally distributed, but this dis-
tribution may vary in width over the concentration
interval.
The concentration random error ei contains several
potential components, all of which are covered in the
Clinical Laboratory Standards Institute document
EP5-A3 (3 ). Those components that are introduced
within a calibration interval (on a specific instrument
using specific reagents), such as repeatability, between-
operator, between-run, and between-day imprecision,
are equal to the signal random error i from these sources
divided by the slope of signal vs concentration on the
calibration curve at position i. Thus, assuming a symmet-
ric distribution:
within calibration:ei  i/ (5)
The calibration to calibration random error component
of ei is a function that modifies the underlying calibrator
fit function fi. The decision by the manufacturer to use a
master calibration curve plus a small set of product cali-
brators (adjustors) vs using a larger set of product calibra-
tors represents 2 ways to minimize this error component.
In the first case, a manufacturer may create the mas-
ter calibration curve equation (curve shape) using multi-
ple IVDmedical devices and replicates overmultiple runs
for a specific reagent lot. The manufacturer will then
value assign the 1- or 2-level calibrator set that adjusts this
curve for each calibration in the laboratory. This error
component comprises within-calibration variations on
measurement of the small set of adjustors, medical device
to medical device differences in curve shape from the
master curve, changes in curve shape with reagent aging,
and the inability of 1 or 2 adjusters to accurately correct
for systematic shifts in the curve.
In the second case, a manufacturer uses multiple cali-
brator concentration levels to customize the calibration
curve for any specific reagent lot of any age on any instru-
ment. The primary source of variation is the within-
calibration variation on measurement of each calibrator
concentration. A recent report on the effect of using mul-
tiple calibrations to increase measurement trueness sup-
ports this point (4 ). Using a mathematical model such as
a linear regression or 4-parameter logistic curve canmod-
erate the effects of this variation, but, as seen above, if this
model is not a good fit to the actual kinetics of the MP,
then fi can drift away from systematic unity.
The remaining components of ei are because ofmed-
ical device to medical device and reagent lot-to-lot differ-
ences. These errors are not corrected by calibration and,
therefore, are other sources of systematic error above and
beyond error hi caused by RM noncommutability. These
sources of error must be kept in mind whenever general-
ized statements aremade about commutability properties
of an RM with specific MPs. However, the actual equa-
tion used to estimate CS values ignores all the systematic
error terms and combines all the random error compo-
nents into the single term
xˆi   yi  /  ei (6)
When the systematic error terms are removed and disre-
garded by using this equation, different MPs provide
different results for the sameCS even if replication is used
to reduce random error. Disregarding each systematic
error function has different implications and effects. Dif-
ferent methods are used to reduce each of their
magnitudes.
SYSTEMATIC ERRORS
The function f can influence MP results regardless of the
type of calibration curve. If a linear fit is a good but not a
perfect representation of the relationship between signal
and concentration, the resultant calibrationmodel fit and
the resultant function f could look like the example in
Fig. 1. In this case, a linear calibration fit is heavily
weighted at low concentrations. If this function shape is
seen in repeated calibrations, the manufacturer may wish
to change the calibration model to, for example, a qua-
dratic function rather than a linear function. If, however,
the ratio function is not consistent from calibration to
calibration, then the linear model may still be the best
option. These considerations are valid whether multi-
point calibrations are performed by the clinical labora-
tory when using an MP or whether a multipoint calibra-
tion is performed by the manufacturer and 1- or 2-point
adjustments are made by the clinical laboratory.
The function g is influenced by the process of pre-
paring the MP calibrators. A common approach begins
with a high concentration standard preparation of ana-
lyte that can be diluted gravimetrically or volumetrically
with matrix containing zero analyte. The resulting seri-
ally diluted series of calibrator samples containing pro-
portionally related fractional amounts of analyte com-
pared with the initial concentrated material typically
produces a highly linear relationship between amount of
measurand and fractional dilution. In other cases, if, for
example, an equilibrium must be reached between free
and bound analyte, a distinctly nonlinear relationship
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may be observed, and other means must be used to de-
termine the amount of measurand in each calibrator sam-
ple in the dilution series. A calibrator dilution series that
provides proportional results (i.e., f  1), by definition,
also provides linear results (intended vs actual levels can
be fit to a straight line). If an MP using proportionally
related calibrators does not provide the correct concen-
tration of a commutable RM or does not mimic the re-
sults for CSs from a referenceMP, then the concentration
of the initial high concentration standard preparation of
the analyte, and, thus, the dilutions to prepare product
calibrators, may be adjusted by a multiplier to provide
true values over the entire measuring interval (i.e., setting
g  1).
Just because a calibrator dilution series is linear does
not mean its results are proportional. This discrepancy
can occur if the serial dilutions are not prepared correctly
or if the dilution matrix contains some small amount of the
analyte. In these cases, theremay be need for an offset at zero
concentration that translates into an increased actual to in-
tended amount of substance ratio at low concentrations.
This discrepancy is shown in the example in Fig. 2. In this
example, the bias from the true concentration at the highest
concentration is about13%, but the contribution of the
dilutionmatrixmoves this actual to intended concentration
ratio higher at lower concentrations.
Even if calibration provides proportionality (f  1)
and the calibration system has been aligned to match
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Fig. 1. Example systematic error over themeasuring interval owing to a calibration scheme that does not capture the true relation-
ship between signal and measurand value.
(A) shows the calibrationﬁt of the observeddata. The line is the calibrationmodel ﬁt, and thepoints are theobserved calibrationdata. (B) shows
the function f for the observed calibration ﬁt.
Special Reports
468 Clinical Chemistry 64:3 (2018)
the value of the RM (g  1), the RM may not be
commutable with an MP (h  1) with the effect that
dilutions of the RMmade to match the concentrations
of CSs do not give the sameMP response as for the CSs
containing the same amount of measurand. This non-
commutability phenomenon is difficult to measure di-
rectly. A common way to visualize it is to compare
results for CSs and RMs intended for use as calibrators
between 2 different MPs using a plot of results for
CSs and RMs (5 ). As with the other 2 functions (f
and g) mentioned above, any bias owing to noncom-
mutability (function h) may be constant across the
measuring interval or may vary in magnitude with
concentration.
Commutability Assessment by the Calibration
Effectiveness of a Reference Material
GENERAL CONSIDERATIONS
Manufacturers of an RMmust ensure that their material
is fit for the purpose of being a higher order calibrator in
the traceability chain of lower order product calibrators
from multiple MPs. MPs can be excluded from the com-
parison if
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Fig. 2. Example systematic error from a serial calibrator dilution process that provides actual amounts of measurand that are not
proportional to the intended amounts.
(A) shows the calibration ﬁt of the calibrator dilution series. The line is unity for a one-to-one relationship between actual and intended
concentrations of the calibrators, and thepoints are the observed concentrations of thediluted calibrator series. (B) shows the functiong for the
actual and intended concentrations.
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• MP results have high imprecision (e),
• A poor fitting mathematical model or a suboptimal
fitting algorithm is used for calibration (function f 
1), or
• The MP is relatively sensitive to individual sample-
specific interferences.
For the commutability assessment, the baseline assump-
tions are that when a single RM is used in the calibration
hierarchy chain to recalibrate each medical laboratory
MP, that
• The RM will be commutable compared with CSs
(function h  1), and
• The resultant rescaling will align the clinical laboratory
MP product calibrators to their correct values (func-
tion g  1).
If these assumptions are met, then recalibrated clinical
laboratory MPs will give equivalent CS results, within an
acceptability criterion, across the concentration interval
and, subsequently, the RM can be said to be commut-
able. If someMPs give different results after recalibration
with the RM, then remaining sources of error must be
investigated before concluding that the RM is noncom-
mutable for those MPs.
The following example describes a method of assess-
ing the commutability of an RM (function h) across mul-
tipleMPs using a set of CSs. A requirement for theMP to
MP variability for CS results is specified (e.g., bias
range 	 6%) as the criterion for commutability. This
variability is measured as the intermeasurement proce-
dure bias range (IMPBR). The accurate determination of
this parameter depends on the robust determination of
bias for each MP regardless of imprecision or interfer-
ences. The underlying assumption is that a single bias
estimate can be provided for each MP (i.e., bias does not
depend on concentration). This assumption should be
tested. In the following description, an example data set is
used to illustrate the process of assessing RM commut-
ability by the RM’s effectiveness to improve the agree-
ment of results for a set of CSs after recalibration of the
MPs with the RM. The analyses described assume 32
CSs (6 ) and 	20 MPs (7 ). The cited articles can be
referenced for different order statistic options if fewer
CSs or more MPs are used.
MEASUREMENT PROCEDURE SCREENING
A set of CSs is obtained per specifications [see part 1 of
this series (2 )] that reasonably covers the expected con-
centration interval of the candidate RMs to be assessed
for commutability. Each CS and RM level provided is
measured using each MP with sufficient replication to
meet the uncertainty requirements for the study. The
replication for each of the small number of RM levels will
be more extensive than for each of the many CSs with the
RMs distributed in several positions among the CSs in
the sequence of measurements by each MP. In addition,
the testing sequence for CSs should be random regarding
concentration. An example of a detailed experimental
design is given in part 2 of this series (8 ). The concentra-
tion error term ei and its variance components must be
considered for each MP in designing and performing
such a study. The mean of the replicate results for each
CS is used in subsequent calculations for comparing the
agreement among results for various MPs.
Table 1 in the onlineData Supplement shows results
from 40 CSs for 7 MPs (labeled MP1–MP7) using each
MP’s manufacturer-specified calibration scheme plus an
across-MP target result. Given an assumption of normal-
ity across MP results for each CS and the number (n) of
MPs is	20, themost robust estimate of central tendency
(target result) is the trimmed mean (T ) (7 ) of the MP
results for each CS (X  ordered results) computed as
T 
i  2n  1Xi
n  2
(7)
Other options for estimatingT are available for situations
when data are censored or the underlying distribution
cannot be assumed to be normal (9 ). Alternative meth-
ods have been described in efforts to harmonize results
across MPs (10–12). Note that the sample identifiers
(IDs) in Table 1 of the online Data Supplement are
ranked in order of increasing trimmed mean (target re-
sult) concentration.
These data can also be represented by a plot with the
percent difference from the trimmed mean target plotted
against the sample ID, as seen in Fig. 3. The sample ID is
related to sample concentration value, with higher sam-
ple IDs having higher concentration values (see Table 1
in the online Data Supplement for concentrations). This
plot is the best way to see whether specific samples behave
differently (e.g., because of interferences) across different
MPs because the IDs are aligned and evenly spaced. Scal-
ing in this way directly displays overall bias for each MP
at each CS. Viewing this plot, it is seen that MP1 results
are close to the trimmed mean target, whereas the other
MS results (labeled MP2–MP7) range from approxi-
mately 50% higher to 30% lower than the target re-
sults. The actual median bias differences are listed in
Table 1. If desired, median CIs may be determined per
Clinical Laboratory Standards Institute document EP09
(13 ).
Sample 14 gives outlying results for most of the
MPs, which could be used as a reason to exclude this
sample from this analysis or from future testing. Sample 7
gives a high outlying result for MP3, indicating a poten-
tial interference specific to that sample on MP3. These 2
samples are retained in the following analysis because the
order statistics used are robust enough to not be overly
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influenced by such outlying results. Because of the out-
lying result, MP3 appears to have higher imprecision
than the other MPs, which is seemingly confirmed by
measuring the SD of the percent differences over all CSs
(9.5% forMP3, 4.0% forMP1, and 5.7% forMP2).How-
ever, a more robust variability estimate called the quasi-
range (6)W(3) scaled toMP1gives 5.9% forMP3, 4.0% for
MP1, and 5.6% for MP2 (see Table 2 here and the online
Data Supplement for a description of this technique).
Therefore, there is no compelling reason to eliminate MP3
from consideration in this analysis. Suchmeasures of impre-
cision could be used, however, to determine whether more
replication is warranted for selected MPs.
MP7 results have a consistent offset from the target
except at the highest concentrations for which the bias
changes with concentration. MP4 has a steadily increas-
ing bias as results get lower in concentration. Except for
the trends noted for MP4 andMP7, all other MPs have a
relatively consistent percent difference from target values.
When trends are apparent, as with MP4 and MP7, the
median may not provide accurate estimates of overall
bias. This situation will be addressed later during consid-
erations for recalibration.
Table 1 (Measurement procedure screening) pres-
ents additional calculations of the median percent bias
(from target) over all 40 samples for each MP for the
screening results. In addition, the IMPBR over the 7MPs
is also provided. This IMPBR is the value that can be
compared with the maximum cross-MP commutability
criterion described above as 6%. Because theMPs are not
yet standardized to the RM, the resultant high IMPBR of
76.6% is not unexpected, indicating that the next steps in
the process should be followed.
USING A REFERENCE MATERIAL FOR CALIBRATION
TRACEABILITY
The next step in the commutability assessment is to de-
termine whether the RM(s) when used for recalibration
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Fig. 3. Difference in percent from the target value (trimmed mean) for each of 40 CS original results from 7 MPs.
The median difference for each MP is shown as the square symbol, along with the MP identiﬁers to the right.
Table 1. Median percent biases across all CSs for each MP and IMPBR across all MPs.
MP1 MP2 MP3 MP4 MP5 MP6 MP7 Bias range (IMPBR)
Results from measurement
procedure screening
Median bias, % −0.4 9.5 20.7 46.6 −30.0 −19.4 −11.4 76.6
Results from commutability
assessment after recalibration
Median bias, % −0.8 −0.3 −0.2 −0.3 0.4 −21.3 −1.1 21.6
Median bias excluding MP6, % −0.8 −0.3 −0.2 −0.3 0.4 Exclude −1.1 1.5
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of the MPs can reduce the IMPBR. The recalibration
effort must consider both the random errors inherent in
the calibration process i and the potential lack of fit
described by the function fi. The plot from Fig. 3 can be
reviewed to determine whether a single concentration
level of RM can be used to recalibrate the MPs. The
imprecision seenwithin theCS andRM samples could be
used to determine whether enough replication was used
to meet the uncertainty requirements of the study on
each MP. As noted, most of the MPs have a consistent
proportional offset from the target values. This offset was
measuredwith a least-squares linear regression ofMP bias
vs trimmed mean for MP1, MP2, MP3, MP5, and MP6
with all P values of the slope0.17. This P value implies
that for those MPs a single RM level can be used to
proportionally correct the bias from the target (i.e., set
g  1).
MP4 showed an increasing bias at lower concentra-
tions (slope P value	 0.0001). Such a change over con-
centration can be caused by a poor calibration fit (f 1)
or errors in creating calibration material (g  1). The
shape of theMP4 bias plot implies that there is a constant
offset in addition to a proportional offset. These offsets
could be corrected by using a set of RMs with at least 2
concentrations of the measurand. Given the relatively
linear slope of MP4 bias over the concentration interval,
such a strategy could bring it into alignment with the rest
of the MPs. However, it would not address the poten-
tially poor design and implementation process used in
creating this MP. It is recommended that the RM pro-
vider describe to the MP manufacturer how their MP
results differ from the other MP results so that the man-
ufacturer can investigate potential design issues.
Further investigation may be required to determine
the path forward for MP7 (slope P value  0.0497).
Typically, the process of making calibration material af-
fects low concentration samples more than high concen-
tration samples, as seen with MP4, so function g is un-
likely to play a role here. This observation is more likely
to be an issue of poor calibration fit (f  1), which is a
function of MP design (see Fig. 1). Therefore, although
such variation could potentially be corrected by provid-
ing 3 concentration levels of the RM, the RM manufac-
turer should not be expected to solve individual MP de-
sign issues. Again, the RM provider should describe to
the MP manufacturer how their MP results differ from
the other MP results so that the manufacturer can inves-
tigate potential design issues. MP3 had a large outlying
result for sample 7, suggesting a sample interferent dif-
ferent from any other MP. The RM provider can decide
whether to drop sample 7 from consideration with MP3
or to drop MP3 from the list of MPs to be assessed for
commutability. Regardless of this decision, theMPman-
ufacturer should be notified of the identified issue.
EFFECTIVENESS OF RECALIBRATION WITH THE RM AS AN
ASSESSMENT OF COMMUTABILITY
The general approach is to substitute the candidate RM
to be assessed for commutability for the RM currently
used by an MP manufacturer in the MP’s calibration
traceability scheme. In other words, the RM to be as-
sessed for commutability should be used directly as a
calibrator for the clinical laboratory MP or as a calibrator
for a manufacturer’s value transfer procedure in its trace-
ability scheme as described in ISO 17511 (1 ). The set of
CSs are then remeasured with each MP now having its
calibration traceable to the candidate RM.
Table 2 in the onlineData Supplement shows results
from the same 40 CSs after the 7 MPs (labeled MP1C–
MP7C) have been recalibrated using the candidate RM.
The option of using a 2-level RM was chosen for all MPs
to correct for the bias seen in MP4 and any residual
constant bias not identified by the difference plots for the
other MPs. These adjusted product calibrator values
could be used to recompute the concentrations from the
signals obtained from the original CS measurements
without repeating the experiment. Alternatively, this ad-
justment could be made to the product calibrator levels
and the CS then measured again using the MP with the
new calibration. The first approach is preferred to avoid
incremental measurement error introduced by the sec-
ond approach.
The results for the set of CSs after recalibration can
be represented by a difference plot as seen in Fig. 4.
Before discussing the plots in Fig. 4, it is useful to review
the assumptions that underlie the analyses that have been
Table 2. Measures of sample to sample variation of percent differences from the target value for each MP.
MP MP1 MP2 MP3 MP4 MP5 MP6 MP7
SD before calibration, % 4.01 5.72 9.54 6.73 4.59 5.30 5.65
Adjusted W(3) before calibration, % 4.01 5.57 5.90 5.89 3.49 3.96 4.63
SD after calibration, % 4.05 4.99 7.83 3.80 6.34 4.89 6.45
Adjusted W(3) after calibration, % 4.05 4.98 4.95 3.45 4.39 3.57 5.06
SD for each MP over all CSs.
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done. First, the use of robust measures of bias has reduced
the effects of random variation and sample-specific inter-
ferences on the measurements of bias. Second, systematic
error can be completely described for each MP by the
functions f (calibration fit), g (calibrator value assign-
ment), and h (RM commutability). Third, by definition,
the use of the RM for calibration traceability sets func-
tion g 1. Fourth, the use of a 2-level RMwill correct for
errors in functions f even if they are offsets that change in
a linear fashion over concentration. Fifth, any remaining
bias is owing to noncommutability (function h) or the
inability of a linear correction to adjust for calibration
lack of fit (function f ).
The plots in Fig. 4 indicate that for MP1 through
MP5 andMP7 the median biases are close to zero. Given
the above assumptions and lack of slope for MP4, it can
be concluded that for MP1 through MP5 the recalibra-
tion using the RM set the function g 1 and adjusted for
any issues with calibration fit (function f ). In addition,
the RMwas commutable with CS forMP1 throughMP5
(function h 1). TheMP6median bias is different from
zero. For MP6, the bias is consistent over the concentra-
tion interval. Therefore, because g  1 and there are no
indications of inconsistent bias over the concentration
interval, then f 1 as well. Assuming sources of random
error have been reduced by study design, the remaining
source of error is the systematic error function h, meaning
that the RM is not commutable with MP6.
MP7 is problematic. Although its median percent
difference from target is close to zero, the linear adjust-
ment did not eliminate the decreasing bias trend at the
highest concentrations. Therefore, the bias is not consis-
tent across the concentration interval and the median is
not an accurate description of overall bias for MP7. The
inconsistent bias is presumably because f  1 at higher
concentration. It is an open question whether this bias is
because of a consistent systematic calibration error or the
specific calibration(s) used in this study. The effect of the
calibration to calibration random effect could be reduced
by increasing the number of calibrations (4 ).
The bias analysis was performed on the data in Table
2 in the online Data Supplement with the results shown
in the second part of Table 1 here (Commutability assess-
ment after recalibration). Again, the IMPBR is compared
with the predetermined criterion. In this case, the esti-
mate of 21.6% still does not meet the commutability
requirement of IMPBR 	 6%. However, the median
MP to MP variability has been notably reduced (i.e.,
from 76.6%). The median bias for MP6 is much larger
than the other MPs. This excess bias indicates that the
RM is not suitable for use with MP6. This observation
does not necessarily mean the RM has a problem, but
simply that it is not commutable for MP6 and cannot be
used to provide calibration traceability for MP6. There-
fore, MP6 should be excluded from the assessment of
RM suitability. After excluding MP6, the bias range re-
duces to 1.5%, which meets the 6% IMPBR criteria.
Recalibration will not change the overall sample to
sample variability. Evidence for this statement is shown
in Table 2, which, for each MP, presents the SD of the
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Fig. 4. Difference in percent from the target value for the same 40 CS results after recalibration of the 7 MPs shown in Fig. 3 with
traceability to the RM.
Themediandifference for eachMP is shownas the square symbol, alongwith theMP labels to the right.Note that theMP6median is separated
from the other medians that are difﬁcult to distinguish from each other. The MP colors are the same as in Fig. 3. MP7 is the dark blue symbol
as pointed out on the ﬁgure.
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percent differences over all CSs and the quasi-range W(3)
adjusted to theMP1 SD (see the onlineData Supplement
for a discussion of this technique). The only exception is
MP4, for which before recalibrationW(3) was 5.89% and
afterward was 3.45%. This change is because before reca-
libration the variability estimate wasmade over a bias that
changed with concentration. After recalibration, this
change in bias over concentration was eliminated and the
variability was subsequently reduced.
Recalibration with RM also cannot solve the inci-
dence of measurement interferences seen in some indi-
vidual CSs with someMP results, nor can the 2-level RM
chosen in this example solve the nonlinear issues seen for
MP7. An RM with a different concentration level or
additional RMs may be considered to address the non-
linearity (f  1) seen for MP7. Alternatively, it is neces-
sary for the manufacturer of MP7 to improve the mea-
surement performance. It is not the responsibility of the
RM manufacturer to solve the problems of IVD manu-
facturers. However, it is important for RM manufactur-
ers to work collaboratively with IVD manufacturers to
ensure the RM(s) will be generally suitable for use. The
MP6 manufacturer should be notified that their results
were excluded to reach the IMPBR specification and the
RM was not commutable for use with MP6.
Conclusion
A process of assessing the commutability of an RM has
been described that uses a set of CSs to determine bias
between MPs. Robust methods of determining bias (i.e.,
difference from trimmedmean of all MP results) are used
to reduce the effects of imprecision and sample-specific
interferences. The sources of bias have been elucidated by
describing their various effects on the calibration process
used by each MP to provide CS results. The sources of
bias include lack of calibration fit, calibrator bias, and
noncommutability. When a candidate RM is used as the
highest-level material in the traceability scheme for each
MP, the resultant CS bias estimates can help separate the
overall bias into these constituent sources of error. This
process can identify those MPs whose bias can be elimi-
nated through use of the candidate RM, those MPs
whose design may need to be updated, and thoseMPs for
which the RM is noncommutable with CSs.
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